ERBB2 and inflammatory breast carcinoma: Currently, the molecular classification and treatment of IBC are modelled after those for nIBC [5], yet notable differences exist in subtype prevalence (e.g., HR: 30% in IBC vs. 60%–80% in nIBC; HER2-positive: 40% in IBC vs. 25% in nIBC; triple-negative: 30% in IBC vs. 10%–15% in nIBC) and treatment efficacy [6].